Compare RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs 10X Genomics Inc — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B), while 10X Genomics Inc trades at $72.38 (market cap $9.35B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 6.8× 10X Genomics Inc's market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays a 2.49% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RELX | TXG | |
|---|---|---|
Market Cap | $63.57B | $9.35B |
Volume | 1,602,093 | 4,039,449 |
Sector | Industrials | Health |
52-Week High | $46.80 | $97.74 |
52-Week Low | $27.73 | $11.83 |
Enterprise Value | $75.05B | $8.88B |
Dividend Yield | 2.49% | — |
Typical Hold Time | — | 91 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.
The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
